A cohort of patients manifesting early dyskinesia have been identified and followed with repeated ratings and videotaped recordings. Preliminary analyses of the first 53 patients completing a year or more of followup has been completed. Support is now requested to increase the early dyskinesia sample to over 200 patients and to follow them from two to six years. The change in early dyskinesia over time will be assessed and factors affecting the course of dyskinesia including antipsychotic drug therapy and other patient characteristics will be studied. A complimentary group of patients with late persistent dyskinesia will also be followed for two to four years. Their course will be compared with that of the early dyskinesia patients. Neuroleptic plasma levels will be added to the periodic ratings both to determine the relations between such levels and changes in dyskinesia and to determine whether such levels predict clinical relapse or other side effects. A double-blind study of patients on depot fluphenazine decanoate is also proposed involving sixty patients, twenty of whom will remain on their original dose while forty will have their dose decreased 40%. The relationships between neuroleptic plasma levels, psychiatric status, dyskinesia, and neurological side effects will be studied as will phenomena suggestive of supersensitivity psychosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH032675-08
Application #
3375364
Study Section
(TDAB)
Project Start
1979-04-01
Project End
1988-06-30
Budget Start
1986-12-01
Budget End
1988-06-30
Support Year
8
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Boston Mental Health Foundation
Department
Type
DUNS #
City
Belmont
State
MA
Country
United States
Zip Code
02178
Gardos, G; Casey, D E; Cole, J O et al. (1994) Ten-year outcome of tardive dyskinesia. Am J Psychiatry 151:836-41
Yonkers, K A; Kando, J C; Cole, J O et al. (1992) Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 149:587-95
Cole, J O; Gardos, G; Boling, L A et al. (1992) Early dyskinesia--vulnerability. Psychopharmacology (Berl) 107:503-10
McElroy, S L; Dessain, E C; Pope Jr, H G et al. (1991) Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 52:411-4
Gardos, G; Cole, J O; Haskell, D et al. (1988) The natural history of tardive dyskinesia. J Clin Psychopharmacol 8:31S-37S
Gardos, G; Perenyi, A; Cole, J O et al. (1988) Seven-year follow-up of tardive dyskinesia in Hungarian outpatients. Neuropsychopharmacology 1:169-72
Gardos, G; Cole, J O; Schniebolk, S et al. (1987) Comparison of severe and mild tardive dyskinesia: implications for etiology. J Clin Psychiatry 48:359-62
Gardos, G; Cole, J O; Salomon, M et al. (1987) Clinical forms of severe tardive dyskinesia. Am J Psychiatry 144:895-902